Xerosis and pruritus as major EGFRI-associated adverse events

PURPOSE: The objective of this sub-analysis of the BeCet study (NCT01136005) was to examine health-related quality of life (HRQoL) of patients experiencing dermatological adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor inhibitor (EGFRI) treatment. METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Clabbers, Julia M. K., Boers–Doets, Christine B., Gelderblom, Hans, Stijnen, Theo, Lacouture, Mario E., van der Hoeven, Koos J. M., Kaptein, Adrian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689742/
https://www.ncbi.nlm.nih.gov/pubmed/26111953
http://dx.doi.org/10.1007/s00520-015-2781-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689742/
https://www.ncbi.nlm.nih.gov/pubmed/26111953
http://dx.doi.org/10.1007/s00520-015-2781-y

Ejemplares similares